How to buy Global Blood Therapeutics stock

Global Blood Therapeutics, Inc is a biotechnology business based in the US. Global Blood Therapeutics shares (GBT) are listed on the NASDAQ and all prices are listed in US Dollars. Global Blood Therapeutics employs 389 staff and has a trailing 12-month revenue of around USD$123.8 million.

How to buy shares in Global Blood Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Global Blood Therapeutics. Find the stock by name or ticker symbol: GBT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Global Blood Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Global Blood Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Global Blood Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Active investors

Webull

Our top pick for

Building a portfolio

Sofi Invest

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.

What's in this guide?

1. GBT shares summary
2. Compare share dealing platforms
3. Is GBT stock a buy or sell?
4. Stock performance over time
5. Can I short GBT shares?
6. Global Blood Therapeutics's financials
7. How volatile are GBT shares?
8. Does Global Blood Therapeutics pay a dividend?
9. Other common questions

Global Blood Therapeutics share price

Use our graph to track the performance of GBT stocks over time.

Global Blood Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-02.

52-week range	USD$36.49 - USD$83.69
50-day moving average	USD$48.5364
200-day moving average	USD$51.1623
Wall St. target price	USD$84.63
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.645

Buy Global Blood Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options, Mutual funds	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Global Blood Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Global Blood Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Global Blood Therapeutics shares

There are currently 11.5 million Global Blood Therapeutics shares held short by investors – that's known as Global Blood Therapeutics's "short interest". This figure is 1.6% up from 11.4 million last month.

There are a few different ways that this level of interest in shorting Global Blood Therapeutics shares can be evaluated.

Global Blood Therapeutics's "short interest ratio" (SIR)

Global Blood Therapeutics's "short interest ratio" (SIR) is the quantity of Global Blood Therapeutics shares currently shorted divided by the average quantity of Global Blood Therapeutics shares traded daily (recently around 1.0 million). Global Blood Therapeutics's SIR currently stands at 11.42. In other words for every 100,000 Global Blood Therapeutics shares traded daily on the market, roughly 11420 shares are currently held short.

However Global Blood Therapeutics's short interest can also be evaluated against the total number of Global Blood Therapeutics shares, or, against the total number of tradable Global Blood Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Global Blood Therapeutics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Global Blood Therapeutics shares in existence, roughly 190 shares are currently held short) or 0.2156% of the tradable shares (for every 100,000 tradable Global Blood Therapeutics shares, roughly 216 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Global Blood Therapeutics.

Find out more about how you can short Global Blood Therapeutics stock.

Global Blood Therapeutics share price volatility

Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $36.49 up to $83.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 1.1211. This would suggest that Global Blood Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Global Blood Therapeutics overview

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Global Blood Therapeutics is owned by insiders or institutions?

  Currently 1.772% of Global Blood Therapeutics shares are held by insiders and 108.404% by institutions.

• How many people work for Global Blood Therapeutics?

  Latest data suggests 389 work at Global Blood Therapeutics.

• When does the fiscal year end for Global Blood Therapeutics?

  Global Blood Therapeutics's fiscal year ends in December.

• Where is Global Blood Therapeutics based?

  Global Blood Therapeutics's address is: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

• What is Global Blood Therapeutics's ISIN number?

  Global Blood Therapeutics's international securities identification number is: US37890U1088

• What is Global Blood Therapeutics's CUSIP number?

  Global Blood Therapeutics's Committee on Uniform Securities Identification Procedures number is: 37890U108